Literature DB >> 8025284

Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells.

G Roth1, T Curiel, J Lacy.   

Abstract

The Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) is a latent viral protein that is expressed in all EBV-immortalized lymphocytes and plays an essential role in immortalization y EBV. EBNA-1 protein is required for replication and maintenance of the episomal viral genome in latently infected, immortalized cells. Given the essential function of EBNA-1 in immortalization, we have examined the effect of EBNA-1 antisense oligodeoxynucleotides on expression of EBNA-1 protein and proliferation in EBV-immortalized lymphoblastoid cells. We have shown that exposure to unmodified antisense oligodeoxynucleotide of codons 6 through 10 of EBNA-1 partially suppressed EBNA-1 protein expression in EBV-immortalized lymphoblastoid cells relative to untreated cells or cells exposed to two scrambled sequences of the EBNA-1 antisense. Furthermore, EBNA-1 antisense inhibited proliferation of EBV-immortalized cells by at least 50% compared with the scrambled antisense sequences. There was no difference in the effect of antisense and scrambled antisense oligodeoxynucleotides on the proliferation of EBV-negative cells, indicating that the antiproliferative effect of EBNA-1 antisense was EBV-specific. These findings underscore the essential role of EBNA-1 in immortalization and, furthermore, have potential therapeutic implications for EBV-associated neoplastic diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8025284

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes.

Authors:  S Huang; D Stupack; P Mathias; Y Wang; G Nemerow
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  Identification and characterization of a cell membrane nucleic acid channel.

Authors:  B Hanss; E Leal-Pinto; L A Bruggeman; T D Copeland; P E Klotman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening.

Authors:  Ning Li; Scott Thompson; Hualiang Jiang; Paul M Lieberman; Cheng Luo
Journal:  Expert Opin Drug Discov       Date:  2010-12       Impact factor: 6.098

4.  Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance.

Authors:  Myung-Soo Kang; Eun Kyung Lee; Vishal Soni; Timothy A Lewis; Angela N Koehler; Viswanathan Srinivasan; Elliott Kieff
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

5.  Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.

Authors:  Mei Hong; Yoshihiro Murai; Tomohiko Kutsuna; Hiroyuki Takahashi; Kazuhiro Nomoto; Chun-Mei Cheng; Shin Ishizawa; Qing-Li Zhao; Ryohei Ogawa; Brian V Harmon; Koichi Tsuneyama; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2005-09-23       Impact factor: 4.553

6.  Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome.

Authors:  Eun Kyung Lee; Sun Young Kim; Ka-Won Noh; Eun Hye Joo; Bo Zhao; Elliott Kieff; Myung-Soo Kang
Journal:  Antiviral Res       Date:  2014-01-31       Impact factor: 5.970

7.  Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC-MSB1 MDV-transformed lymphoblastoid cells.

Authors:  Q Xie; A S Anderson; R W Morgan
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Down-regulation of Epstein-Barr virus nuclear antigen 1 in Reed-Sternberg cells of Hodgkin's disease.

Authors:  G Khan; M A Naase
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

Review 9.  EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers.

Authors:  Lijun Jiang; Chen Xie; Hong Lok Lung; Kwok Wai Lo; Ga-Lai Law; Nai-Ki Mak; Ka-Leung Wong
Journal:  Theranostics       Date:  2018-10-22       Impact factor: 11.556

Review 10.  EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers.

Authors:  Joanna B Wilson; Evelyne Manet; Henri Gruffat; Pierre Busson; Marc Blondel; Robin Fahraeus
Journal:  Cancers (Basel)       Date:  2018-04-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.